Get the Stockscreener App
11.27
2.00%
-0.23
After Hours:
11.27
Bausch Lomb Corp stock is traded at $11.27, with a volume of 657.30K.
It is down -2.00% in the last 24 hours and down -10.06% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$11.50
Open:
$11.52
24h Volume:
657.30K
Relative Volume:
0.77
Market Cap:
$4.06B
Revenue:
$4.79B
Net Income/Loss:
$-317.00M
P/E Ratio:
-12.38
EPS:
-0.91
Net Cash Flow:
$-59.00M
1W Performance:
-2.00%
1M Performance:
-10.06%
6M Performance:
-43.65%
1Y Performance:
-26.29%
1-Day Range:
$11.10
$11.57
1-Week Range:
$10.83
$11.78
52-Week Range:
$10.45
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
11.27 | 4.06B | 4.79B | -317.00M | -59.00M | -0.91 |
|
ISRG
Intuitive Surgical Inc
|
536.51 | 189.75B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
95.75 | 48.62B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
167.22 | 48.37B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
245.04 | 35.18B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.27 | 16.46B | 3.90B | 392.30M | 288.10M | 1.95 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Bausch + Lomb’s LuxLife Intraocular Lens Gains European CE Mark Approval - TipRanks
Bausch + Lomb (BLCO) Receives CE Mark for LuxLife Intraocular Lens | BLCO Stock News - GuruFocus
Bausch & Lomb (BLCO) Price Target Lowered by Morgan Stanley | BLCO Stock News - GuruFocus
Bausch & Lomb stock target cut to $15 at H.C. Wainwright By Investing.com - Investing.com South Africa
Bausch & Lomb stock target cut to $15 at H.C. Wainwright - Investing.com Nigeria
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwr - GuruFocus
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwright & Co. | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Cut by Analyst Amid Tariff Concerns | BLCO Stock News - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Pr - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Price Target | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Shares Plunge After Weak Q1 2025 Results - GuruFocus
Bausch & Lomb (BLCO) Target Price Lowered by Evercore ISI Group - GuruFocus
Bausch & Lomb (BLCO) Target Price Lowered by Wells Fargo | BLCO Stock News - GuruFocus
Bausch + Lomb Corporation (NYSE:BLCO) Q1 2025 Earnings Call Transcript - Insider Monkey
Bausch + Lomb (BLCO) Faces Price Target Cut Amid Financial Press - GuruFocus
Bausch + Lomb (BLCO) Sees Adjusted Price Target Amidst Earnings Update | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Reports Q1 Revenue Slightly Below Expectati - GuruFocus
Bausch + Lomb (BLCO) Faces Price Target Cut Amid Financial Pressures | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Reduced by Citi After Q1 Repor - GuruFocus
Bausch + Lomb (BLCO) Misses Revenue Expectations in Q1, Shares D - GuruFocus
Bausch + Lomb (BLCO) Misses Q1 Estimates, Lowers Growth Outlook - GuruFocus
Bausch & Lomb Reports Weak Start to 2025 as enVista Recall, Tariffs, and Drug Pricing Cause Concerns - Morningstar
Bausch & Lomb Corp SEC 10-Q Report - TradingView
Bausch + Lomb stock hits 52-week low at $10.46 By Investing.com - Investing.com India
Bausch + Lomb stock hits 52-week low at $10.46 - Investing.com Australia
Bausch + Lomb shares tumble as Q1 earnings miss expectations By Investing.com - Investing.com Canada
Bausch + Lomb shares tumble as Q1 earnings miss expectations - Investing.com
Bausch + Lomb Announces First-Quarter 2025 Results - BioSpace
Bausch + Lomb (BLCO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Bausch + Lomb Reports Q1 2025 Revenue Growth Amid Challenges - TipRanks
Bausch + Lomb Q1 2025 slides: Revenue grows 5% despite enVista recall impact - Investing.com
Bausch + Lomb (BLCO) Updates FY25 Financial Outlook | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Reports Q1 Revenue Slightly Below Expectations | BLCO Stock News - GuruFocus
Bausch + Lomb: Q1 Earnings Snapshot - Barchart.com
Bausch + Lomb Q1 2025 Financial Results - TradingView
Wells Fargo maintains Bausch & Lomb stock with $15 target By Investing.com - Investing.com Canada
Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings - Barchart.com
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall - BioSpace
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb resumes enVista IOL production after recall - Investing.com
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for - MSN
Billionaire Carl Icahn builds 34% economic interest in Bausch Health - Reuters
Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts? - Yahoo Finance
Fitch upgrades Bausch + Lomb rating, maintains evolving watch - Investing.com
Fitch upgrades Bausch + Lomb rating, maintains evolving watch By Investing.com - Investing.com Canada
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg.com
Bausch & Lomb Corp (BLCO) Shares Down 3.1% on Apr 15 - GuruFocus
Bausch & Lomb Agrees to End Vitamin-Patent Suit Ahead of Trial - Bloomberg Law News
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last? - Yahoo
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Bausch + Lomb Recalls Certain EnVista Intraocular Lenses - Nasdaq
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.40%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):